SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Gordon James who wrote (310)9/8/1999 10:40:00 PM
From: Vector1  Read Replies (1) | Respond to of 666
 
Gordon,
Both. I don't think it will matter much. Sales will be driven by post approval phase IIs, marketing and the views of Lymphoma opinion leaders. In additon I think it will be hard for the FDA to limit the label to transformed disease because they clearly met the clinical endpoints for highly treated patients. However, one can never tell with the FDA.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News